Going-concern and liquidity risk
The company has no revenue, recurring losses, and limited cash, so it must raise capital to continue operations.
- Scope
- Biotech development and corporate overhead
- Materiality
- high
GridAI Technologies Corp.
GridAI Technologies Corp. is a U.S.-based biotechnology company that develops targeted, non-systemic therapies for gastrointestinal diseases, with product candidates including Adrulipase, Niclosamide, Capeserod, and Latiglutenase. In September 2025 it also acquired Grid AI Corp., adding an AI-driven grid-edge software and device platform for utilities, energy retailers, and large commercial and industrial customers to its operations.
−17 954,6 %
−1 813,6 %
−17 634,4 %
0.17
0.17
| % | |
|---|---|
| GI drug development programs | 85% Non-systemic therapeutic candidates designed to act locally in the gastrointestinal tract. |
| In-licensed clinical assets | 10% Externally sourced drug programs, including Capeserod, that expand the pipeline. |
| Grid AI software and device platform | 5% AI-driven energy orchestration tools for utilities and large power users. |
The biotechnology side of the business is not yet commercial, so its end customers are future patients and the...
- Future GI therapy patients and providersprimary
Would buy or prescribe approved non-systemic GI treatments such as Adrulipase and Capeserod for localized disease management.
- Utilitiessecondary
Buy Grid AI software to coordinate distributed energy resources, improve reliability, and manage grid conditions.
- Energy retailerssecondary
Use the platform to optimize load, integrate on-site assets, and support customer energy programs.
- Commercial and industrial customerssecondary
Adopt the platform to automate load management and reduce operating costs through better energy coordination.
The company is headquartered in the United States and its reported operations and financing activity are primarily U.S...
- •Headquartered in the United States
- •No disclosed country-level revenue because the company is pre-revenue
- •Development and financing activity are primarily U.S.-based
- •Grid AI may expand exposure to utility and industrial energy markets
- •Geographic risk is currently more funding-related than sales-related
The core strategy remains advancing GI drug candidates while preserving optionality through in-licensing and...
01
Fund the business through equity and debt financingshort-term
The company has no revenue and needs capital to support development and operations.
02
Advance GI pipeline assetsmedium-term
Clinical progress is required to create value from the biotechnology business.
03
Integrate Grid AI and AmpXmedium-term
The acquisition could create a second growth platform and broaden the company’s business model.
The company remains a pre-revenue, development-stage business with substantial going-concern risk and dependence on...
Clinical development failure
Pipeline value depends on successful trials and regulatory approvals for Adrulipase and other candidates.
- Scope
- Adrulipase, Niclosamide, Capeserod, Latiglutenase
- Materiality
- high
Integration risk from Grid AI acquisition
The company is adding a new energy-tech operating component that requires integration, product alignment, and execution.
- Scope
- Grid AI / AmpX platform
- Materiality
- medium
Nasdaq listing compliance risk
The company previously received a bid-price deficiency notice, which can pressure liquidity and investor access.
- Scope
- Capital markets access
- Materiality
- medium
Pre-revenue operating model
Makes quarterly comparisons highly sensitive to development and financing activity
Business combination accounting
Can affect goodwill, intangible assets, and future impairment risk
Stock-based compensation
Inflates operating expenses without immediate cash outflow
Convertible preferred stock and debt
Affects dilution, equity classification, and interest/financing expense
Healthcare AI Acquisition Corp.
Blank Checks
Absci Corp
ABSI · Services-Commercial Physical & Biological Research
Absci Corp is a biotechnology company built around its Integrated Drug Creation platform, which combines AI-driven design, wet-lab biology, and computational…
BioXcel Therapeutics, Inc.
BTAI · Pharmaceutical Preparations
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Lantern Pharma Inc.
LTRN · Pharmaceutical Preparations
AI Technology Group Inc.
Motors & Generators
: 28/04/2026